中国医院药学杂志2024,Vol.44Issue(2) :214-220.DOI:10.13286/j.1001-5213.2024.02.15

基于加权TOPSIS法对阿扎司琼防治CINV合理评价方法的建立与应用

Establishment and application of rational evaluation method of Azasetron used for the prevention and treatment of CINV based on Weighted-Topsis method

刘宇 杨小娟 黄丹 张丽 林波 邹剑 杨孝来
中国医院药学杂志2024,Vol.44Issue(2) :214-220.DOI:10.13286/j.1001-5213.2024.02.15

基于加权TOPSIS法对阿扎司琼防治CINV合理评价方法的建立与应用

Establishment and application of rational evaluation method of Azasetron used for the prevention and treatment of CINV based on Weighted-Topsis method

刘宇 1杨小娟 2黄丹 1张丽 3林波 4邹剑 1杨孝来5
扫码查看

作者信息

  • 1. 彭州市人民医院药学部,四川彭州 611930
  • 2. 四川省妇幼保健院新生儿科,四川成都 610000
  • 3. 彭州市人民医院肿瘤科,四川彭州 611930
  • 4. 海南医学院第二附属医院药学部,海南海口 570102
  • 5. 甘肃省人民医院药剂科,甘肃兰州 730000
  • 折叠

摘要

目的:建立基于加权优劣解距离(TOPSIS)法的阿扎司琼静脉用药防治化疗相关性恶心呕吐(CINV)的药物合理性评价方法,为5-羟色胺3受体拮抗剂(5-HT3RA)临床合理用药提供参考.方法:以盐酸阿扎司琼氯化钠注射液药品说明书及临床应用指南为依据,制订盐酸阿扎司琼氯化钠注射液防治CINV的合理性评价标准.随机调取彭州市人民医院2022年1月至2022年7月使用盐酸阿扎司琼氯化钠注射液的200份病历作为对照组,2022年8月至2023年2月的200份病历作为观察组.基于加权TOPSIS法计算各评价病历与最优方案的相对接近度(Ci),Ci≥80%评价为用药合理,60%≤Ci<80%评价为用药基本合理,Ci<60%评价为用药不合理.采用x2检验对观察组和对照组的合理率进行对比分析.结果:200份对照组病历中,Ci≥80%的有9例(4.50%),60%≤Ci<80%的有43例(21.50%),Ci<60%的有 148例(74.00%).200份观察组病历中,Ci≥80%的有34例(17.00%),60%≤Ci<80%的有64例(32.00%),Ci<60%的有102例(51.00%).观察组与对照组合理率比较,在综合止吐方案(联合用药)、给药时机、药物配伍禁忌及相互作用、生命体征监测、疗效评估方面,差异具有统计学意义.结论:基于加权TOPSIS法制订的盐酸阿扎司琼氯化钠注射液防治CINV中的药物合理性评价方法切实可行,可为其他药物构建标准化的合理用药评价体系提供参考.盐酸阿扎司琼氯化钠注射液不合理应用情况较多,需加强监管力度,以保障患者用药安全.

Abstract

OBJECTIVE To establish a rational drug use evaluation method of intravenous Azasetron used for prevention and treatment of chemotherapy-induced nausea and vomiting(CINV)based on the weighted-technique for order preference by similarity to ideal solution(TOPSIS)method,and to provide references for clinical rational drug use of 5-hydroxytryptamine receptor antagonists(5-HT3RA).METHODS Based on the drug instructions and clinical application guidelines,the rationality evaluation criteria of Azasetron hydrochloride and sodium chloride injection used for the prevention and treatment of CINV were formulated.200 Azasetron hydrochloride and sodium chloride injection utilizing cases that happened in Pengzhou People's Hospi-tal from January 2022 to July 2022 were randomly selected as the control group,and 200 utilizing cases from August 2022 to Feb-ruary 2023 were selected as the observation group.The relative proximity(Ci)between the evaluation medical record and the opti-mal scheme was calculated by using Weighted-Topsis method.Ci≥80%was categorized as rational medication,Ci<60%was categorized as irrational medication,and 60%≤Ci<80%was categorized as nearly rational medication.x2 test was used to ana-lyze the rate of rational medication between the observation group and the control group.RESULTS Among the 200 medical records of control group,there were 9 cases(4.50%)with relative proximity(Ci)≥80%,43 cases(21.50%)with 60%≤Ci<80%,and 148 cases(74.00%)with Ci<60%.Among the 200 medical records of the observation group,34 cases(17.00%)with Ci≥80%,64 cases(32.00%)with 60%≤Ci<80%,and 102 cases(51.00%)with Ci<60%.Compared with the control group,the observation group had statistically significant differences in terms of comprehensive antiemetic regimen(combined medication),administration timing,drug incompatibility and interaction,vital signs monitoring,and efficacy evaluation.CONCLUSION The evaluation method of Azasetron hydrochloride and sodium chloride injection used for the prevention and treatment of CINV based on Weighted-Topsis method is feasible and can provide reference for other drugs to construct standard-ized evaluation system of rational drug use.The results showed that apparently irrational use of Azasetron hydrochloride and sodium chloride injection still persists in clinical practices,which means regulation should be strengthened.

关键词

加权TOPSIS法/盐酸阿扎司琼氯化钠注射液/药物合理性评价/化疗相关性恶心呕吐

Key words

Weighted-Topsis method/Azasetron hydrochloride and sodium chloride injection/drug rationality evaluation/chemotherapy induced nausea and vomiting(CINV)

引用本文复制引用

基金项目

成都市卫生健康委科研项目(2020106)

成都药学会赞邦药学科研基金(202106)

四川医院管理和发展研究中心项目(SCYG2022-03)

出版年

2024
中国医院药学杂志
中国药学会

中国医院药学杂志

CSTPCD北大核心
影响因子:1.198
ISSN:1001-5213
参考文献量19
段落导航相关论文